(MedPage Today) — The FDA on Thursday approved daratumumab-hyaluronidase (Darzalex Faspro) as the first drug for high-risk smoldering multiple myeloma.
Approval of the subcutaneous daratumumab product was based on positive results from the phase…
Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/118369
Author :
Publish date : 2025-11-07 16:45:00
Copyright for syndicated content belongs to the linked Source.
